OakChart

Armata Pharmaceuticals Inc

ARMPHealthcare·Biotechnology·USA·Micro·AMEX·Nov 12 • 3:59 PM ET

3.72-0.17 (-4.37%)
2026-11-13 13:02 CET
Market cap
$138.32M
Revenue, TTM
5.54 USD m
Net income, TTM
-192.18 USD m
Free cash flow, TTM
-25.79 USD m
EPS diluted, TTM
-7.59
Price / earnings
-
Compare

Price

ARMP against its 20, 50 and 200-day averages
Terms2050200Earnings
Patternshover a marker to name it
RS 14EPS -0.40Price-0.42-0.404.006.008.0010.002.4M4.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARMPclose 3.7220-day 3.3650-day 3.83200-day 6.893.7252w low 2.7552-week range, not 6 months

75.2% under the 52-week high of 14.98 on 22 Apr 2026. 52-week low 2.75 on 14 Oct 2026. Last 15 sessions, 39.3% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 14
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 3 of 5 — fails: Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%) — not on the tape: Return on Equity: Over +15%
Quality 0 of 5 — fails: Net Profit Margin: High (>20%); Current Ratio: Over 1 — not on the tape: Return on Equity: Over +15%; Debt/Equity: Low (<0.1); P/E: Under 25
Value 0 of 4 — not on the tape: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

ARMP
52-week range, 8% of the way up
2.7514.98

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

IndexRUT
Employees61
IPOMay 20, 1994
Beta1.63
ATR, 14d0.38
Rel volume0.00
Short float7.67%
Insider own67.99%
Inst own13.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$138.32M
Enterprise Value428.32M
Income-192.18M
Sales5.54M
Book / share-6.22
Cash / share0.64
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees61
IPOMay 20, 1994

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales24.97
Price / book-
Price / cash5.78
Price / free cash flow-
Value / cash profit-
Value / sales77.31
Quick Ratio0.11
Current Ratio0.11
Debt / equity-
Long-term debt / equity-
Options and shortYes / Yes

Earnings

Earnings / share-7.59
Earnings next year-1.45
Earnings next quarter-0.40
Earnings this year61.15%
Earnings next year22.52%
Earnings growth, 5 years38.99%
Past earnings growth-64.55% -28.83%
Past sales growth-3.80% 42.90%
Earnings vs last year-645.64%
Sales vs last year-19.29%
Earnings vs last quarter39.58%
Sales vs last quarter15.72%
EarningsNov 12 AMC
Surprise56.76% 604.67%

Ownership

Insiders own67.99%
Insider trades0.00%
Institutions own13.70%
Institution trades3.09%
Return on assets-225.11%
Return on equity-
Return on capital-
Gross Margin66.88%
Operating margin-636.55%
Profit Margin-3467.04%
20-day average10.55%
50-day average-2.89%
200-day average-45.99%

Technical

Shares out37.15M
Shares floating11.90M
Short / float7.67%
Short ratio5.02
Short interest0.91M
52-week high14.98 -75.2%
52-week low2.75 +35.5%
Volatility12.94% 11.58%
Average range0.38
Strength index53.69
Market sensitivity1.63
Relative volume0.00
Avg Volume181.73K
Volume0

Performance

Perf Week24.00%
Perf Month33.81%
Perf Quarter-18.42%
Perf Half Y-54.63%
Perf YTD-40.76%
Perf Year-44.39%
Perf 3Y44.19%
Perf 5Y10.39%
Perf 10Y-97.29%
Recommendation1.00
Target Price17.50
Prev Close3.72
Price3.72
Change %0.00%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jun 19, 2019InitiatedLadenburg ThalmannBuy$9+141.9%

Peers

Mkt cap
TickerCompanyMkt cap
SPROSpero Therapeutics Inc58.23M
ANTXAN2 Therapeutics Inc168.47M
NIKINiki BioSolutions Inc5.30M
IVVDInvivyd Inc175.89M
ACXPAcurx Pharmaceuticals Inc5.48M
CPIXCumberland Pharmaceuticals Inc99.34M
MCRBSeres Therapeutics Inc14.37M
VIRVir Biotechnology Inc1.79B
TOVXTheriva Biologics Inc7.23M
SCYXScynexis Inc33.14M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
IWMiShares Russell 2000 Index FundAUM: 77.86B
VXFVanguard Extended Market Index ETFAUM: 30.79B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 112.81M
IWCiShares Micro-Cap ETFAUM: 1.23B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.43B
RSSLGlobal X Russell 2000 ETFAUM: 1.44B
ITWOProShares Russell 2000 High Income ETFAUM: 179.79M

News

latest 14 of 200
  • Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update (PR Newswire)
  • Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States (PR Newswire)
  • Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development (PR Newswire) -13.33%
  • Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates (PR Newswire)
  • Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation (InvestorsHub)
  • Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 (PR Newswire)
  • Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
  • Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials (PR Newswire)
  • Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update (PR Newswire) +11.83%
  • Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 (PR Newswire) +12.20%
  • Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia (PR Newswire) -6.81%
  • Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 (PR Newswire)
  • Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update (PR Newswire) -7.03%
  • Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 (PR Newswire)

Quarterly earnings

2026Q3 EPS -0.240 beat -0.555, from -0.740 a year earlier. Sales 3.17 beat 0.45, from 1.16 a year earlier
EPS
0.0000-3.4202024Q4 EPS -0.230 against -0.35024Q42025Q1 EPS -0.200 against -0.38025Q12025Q2 EPS -0.450 against -0.39025Q22025Q3 EPS -0.740 against -0.42025Q32025Q4 EPS -3.420 against -0.28025Q42026Q1 EPS -3.160 against -0.38026Q12026Q2 EPS -0.270 against -0.44526Q22026Q3 EPS -0.240 against -0.55526Q3
Sales, USD millions
3.1702024Q4 sales 1.24 against 1.5624Q42025Q1 sales 0.49 against 1.3825Q12025Q2 sales 2.17 against 1.3825Q22025Q3 sales 1.16 against 1.3825Q32025Q4 sales 1.10 against 0.7425Q42026Q1 sales 0.79 against 0.0026Q12026Q2 sales 2.51 against 0.4026Q22026Q3 sales 3.17 against 0.4526Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-12 16:30-0.240-0.555-0.2403.170.45EPS -56.8% · sales +604.7%vs 2025Q3, year-ago quarter · EPS -67.6% · sales +173.6%2-
2026Q2ended 2026-06-302026-08-12 16:30-0.270-0.445-0.2702.510.40EPS -39.3% · sales +527.5%vs 2025Q2, year-ago quarter · EPS -40.0% · sales +15.7%2Open +0.23% vs SPY +0.31%. Close +11.83% vs SPY +0.70%
2026Q1ended 2026-03-312026-05-13 16:30-3.160-0.380-3.1580.790.00EPS +731.6% · sales -vs 2025Q1, year-ago quarter · EPS +1480.0% · sales +60.7%1Open -1.36% vs SPY +0.18%. Close -7.03% vs SPY +0.79%
2025Q4ended 2025-12-312026-03-25 16:30-3.420-0.280-3.4201.100.74EPS +1121.4% · sales +48.6%vs 2024Q4, year-ago quarter · EPS +1387.0% · sales -10.9%2Open -5.81% vs SPY -0.72%. Close +8.59% vs SPY -1.79%
2025Q3ended 2025-09-302025-11-12 16:30-0.740-0.420-0.7361.161.38EPS +76.2% · sales -16.0%vs 2024Q3, year-ago quarter · EPS +393.3% · sales -61.0%1Open -5.23% vs SPY -0.42%. Close -4.63% vs SPY -1.66%
2025Q2ended 2025-06-302025-08-12 16:30-0.450-0.390-0.4502.171.38EPS +15.4% · sales +57.2%vs 2024Q2, year-ago quarter · EPS +80.0% · sales -1Open +3.66% vs SPY +0.35%. Close +1.63% vs SPY +0.34%
2025Q1ended 2025-03-312025-05-14 16:30-0.200-0.380-0.1810.491.38EPS -47.4% · sales -64.4%vs 2024Q1, year-ago quarter · EPS -71.0% · sales -49.2%1Open +0.01% vs SPY -0.35%. Close +1.45% vs SPY +0.49%
2024Q4ended 2024-12-312025-03-20 16:30-0.230-0.3500.0441.241.56EPS -34.3% · sales -20.8%vs 2023Q4, year-ago quarter · EPS -58.2% · sales -19.2%1Open -1.00% vs SPY -1.10%. Close -10.95% vs SPY -0.27%
2024Q3ended 2024-09-302024-11-13 16:30-0.150-0.280-0.1522.970.90EPS -46.4% · sales +230.3%vs 2023Q3, year-ago quarter · EPS -82.6% · sales +142.7%1Open +0.37% vs SPY +0.02%. Close -1.47% vs SPY -0.64%
2024Q2ended 2024-06-302024-08-13 16:30-0.250-0.370-0.2470.001.15EPS -32.4% · sales -100.0%vs 2023Q2, year-ago quarter · EPS +47.1% · sales -100.0%2Open -2.77% vs SPY +0.15%. Close -10.70% vs SPY +0.32%
2024Q1ended 2024-03-312024-05-07 16:30-0.690-0.310-0.6930.971.10EPS +122.6% · sales -12.2%vs 2023Q1, year-ago quarter · EPS +72.5% · sales +21.4%2Open -1.40% vs SPY -0.36%. Close -3.50% vs SPY +0.01%
2023Q4ended 2023-12-312024-03-21 16:30-0.550-0.285-0.5501.530.84EPS +93.0% · sales +81.9%vs 2022Q4, year-ago quarter · EPS +89.7% · sales +45.4%2Open +0.81% vs SPY -0.02%. Close +1.36% vs SPY -0.19%
2023Q3ended 2023-09-302023-11-14 16:30-0.860-0.255-0.8641.230.95EPS +237.3% · sales +28.9%vs 2022Q3, year-ago quarter · EPS +258.3% · sales -8.4%2-
2023Q2ended 2023-06-302023-08-14 08:30-0.170-0.295-0.0980.981.80EPS -42.4% · sales -45.6%vs 2022Q2, year-ago quarter · EPS -34.6% · sales -48.0%2-
2023Q1ended 2023-03-312023-05-11 16:30-0.400-0.250-0.4020.801.75EPS +60.0% · sales -54.5%vs 2022Q1, year-ago quarter · EPS +33.3% · sales -35.6%2-
2022Q4ended 2022-12-312023-03-16 16:30-0.290-0.215-0.2861.051.67EPS +34.9% · sales -37.1%vs 2021Q4, year-ago quarter · EPS +26.1% · sales +6.3%2-

Annual earnings

2025FY EPS -4.800 missed -1.635, from -0.890 a year earlier. Sales 4.90 beat 4.55, from 5.17 a year earlier
EPS
0.0000-8.9602018FY EPS -8.960 against -7.42020182019FY EPS -2.550 against -1.94320192020FY EPS -1.350 against -1.13520202021FY EPS -0.960 against -0.88320212022FY EPS -1.080 against -0.84020222023FY EPS -1.910 against -1.37020232024FY EPS -0.890 against -0.95020242025FY EPS -4.800 against -1.6352025
Sales, USD millions
6.1502018FY sales 0.00 against 0.0020182019FY sales 0.00 against 0.0020192020FY sales 0.82 against 0.3620202021FY sales 4.47 against 4.4020212022FY sales 5.51 against 6.1520222023FY sales 4.53 against 3.8520232024FY sales 5.17 against 5.5020242025FY sales 4.90 against 4.552025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate--0.180--56.50-
2029FYestimate--0.660--19.00-
2028FYestimate--1.090--0.00-
2027FYestimate--1.445--2.75-
2026FYestimate--1.865--4.25-
2025FY-4.800-1.635-4.8004.904.55-
2024FY-0.890-0.950-0.5235.175.50-
2023FY-1.910-1.370-1.9144.533.85-
2022FY-1.080-0.840-1.0775.516.15-
2021FY-0.960-0.883-0.9614.474.40-
2020FY-1.350-1.135-1.3510.820.36-
2019FY-2.550-1.943-2.4890.000.00-
2018FY-8.960-7.420-50.2560.000.00-
2017FY-30.520-30.380-28.1390.120.10-
2016FY-345.8-152.6-3,4540.260.30-
2015FY-278.6-247.1-278.60.480.50-
2014FY490-4900.41-0.01
2012FY-140-1,890-3.810.40-
2011FY-812-826-0.400.40-
2010FY-735--8402.10--

Quarterly results

2026Q2 revenue 2.51, from 2.17 a year earlier. Operating margin -410.76%, from -315.21% a year earlier
Revenue, USD millions
2.9702024Q3 revenue 2.9724Q32024Q4 revenue 1.2424Q42025Q1 revenue 0.4925Q12025Q2 revenue 2.1725Q22025Q3 revenue 1.1625Q32025Q4 revenue 1.0825Q42026Q1 revenue 0.7926Q12026Q2 revenue 2.5126Q2
Operating margin
0.00-1,6712024Q3 operating margin -328.62%24Q32024Q4 operating margin -850%24Q42025Q1 operating margin -1,671%25Q12025Q2 operating margin -315.21%25Q22025Q3 operating margin -670.69%25Q32025Q4 operating margin -778.7%25Q42026Q1 operating margin -1,113%26Q12026Q2 operating margin -410.76%26Q2

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026Q4 E -0.40 per share.
PeriodTypeScaleDateMeanvs prior date
2026Q4Eper share2026-11-13-0.400.0%
2026Q4Sper share2026-11-130.520.0%
2026FYEper share2026-11-10-1.870.0%
2026Q3Eper share2026-11-10-0.560.0%
2026FYSper share2026-11-104.250.0%
2026Q3Sper share2026-08-130.450.0%
2026Q2Eper share2026-08-09-0.450.0%
2026Q2Sper share2026-07-100.40-4.8%
2026Q1Eper share2026-04-07-0.38-
2026Q1Sper share2026-04-070.00-
2025FYEper share2026-01-27-1.640.0%
2025Q4Eper share2026-01-27-0.280.0%
2025FYSper share2026-01-274.550.0%
2025Q4Sper share2025-12-310.74-50.0%
2025Q3Eper share2025-10-27-0.420.0%
2025Q3Sper share2025-08-131.380.0%
2025Q2Eper share2025-05-15-0.390.0%
2025Q2Sper share2025-05-151.380.0%
2025Q1Eper share2025-03-21-0.38+137.5%
2025Q1Sper share2025-03-211.38-
2024FYEper share2025-01-28-0.950.0%
2024Q4Eper share2025-01-28-0.350.0%
2024FYSper share2025-01-285.500.0%
2024Q4Sper share2025-01-281.560.0%
2024Q3Eper share2024-11-11-0.28+55.6%
2024Q3Sper share2024-10-280.900.0%
2024Q2Eper share2024-07-22-0.370.0%
2024Q2Sper share2024-05-081.150.0%
2024Q1Eper share2024-03-22-0.31+82.4%
2024Q1Sper share2024-03-221.10+10.0%
2023FYEper share2024-01-29-1.370.0%
2023FYSper share2024-01-293.850.0%

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-28.139-50.256-2.489-1.351-0.961-1.077-1.914-0.523-4.796-7.5859-
Sales USD millions0001465556-
Shares million shares1010192736363636-37
Quarterly
MetricQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
EPS per share-0.247-0.1520.044-0.181-0.45-0.736-3.42-3.158-0.272
Sales USD millions031021113
Shares million shares363636363636363637

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue5.544.90-5.2%5.17+14.1%4.53-17.8%5.51+23.3%4.47+445.1%0.820.000.00
Cost of Goods Sold Incl. D&A1.841.53+15.9%1.32+36.1%0.97+9.0%0.89--1.350.0%1.35
Gross Profit3.713.37-12.5%3.85+8.1%3.56-22.9%4.62---1.35-1.35
Selling, General and Administrative Excl. Other38.9934.59-25.3%46.28+4.1%44.45+7.0%41.56+53.2%27.13+27.4%21.30+20.1%17.74+86.0%9.54
Research and Development25.5923.72-31.1%34.43+2.0%33.77-3.6%35.02+74.9%20.02+38.6%14.44+47.0%9.82+17.3%8.37
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-35.28-31.22-42.44-40.89-36.95-23.82-21.59-19.09-10.89
Interest Expense21.3716.59+54.5%10.74+308.4%2.630.00-100.0%0.06-90.5%0.63-32.3%0.93-7.9%1.01
Unusual Expense135.87126.38-33.56-230.5%25.710.00-0.730.00-0.45-108.9%5.04
Net Income Before Taxes-192.18-173.80-18.92-69.05-36.92-23.16-22.18-19.48-16.70
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-192.18-173.80-18.92-69.05-36.92-23.16-22.18-19.48-16.70
Net Income From Continuing Operations-192.18-173.80-18.92-69.05-36.92-23.16-22.18-19.48-16.70
Net Income-192.18-173.80-18.92-69.05-36.92-23.16-22.18-19.48-16.70
EPS (Recurring) per share-3.03-2.35-1.17-1.42-1.08-0.98-1.35-2.53-39.63
EPS (Basic, Before Extraordinaries) per share-5.30-4.80-0.52-1.91-1.08-0.96-1.35-2.49-50.26
EPS (Diluted) per share-7.59-4.80-0.52-1.91-1.08-0.96-1.35-2.49-50.26
EBITDA-33.45-29.69-41.11-39.92-36.05-22.65-20.47-17.74-9.54
Non-Operating Income (Expense)0.350.39-44.3%0.70+288.9%0.18+500.0%0.03+200.0%0.01-66.7%0.03-66.7%0.09-62.5%0.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.722.61-9.7%2.89+207.4%0.94-69.7%3.10+7.6%2.88-17.2%3.48+11.5%3.12+10300.0%0.03
Price To Sales Ratio ratio72.5346.4112.9325.817.7229.5259.53--
Gross Margin %66.8868.7874.3978.5483.81----
Operating Margin %-636.55-636.66-820.18-902.85-670.77-532.45-2,622.96--
Net Margin %-3,467.04-3,544.03-365.60-1,524.51-670.24-517.55-2,695.14--
Shares Outstanding million shares37.1536.43+0.7%36.18+0.2%36.12-0.1%36.14+33.3%27.11+45.1%18.69+88.4%9.92+2655.6%0.36
Market Capitalization138.32138.32+106.6%66.94-42.8%117.11+161.3%44.82-69.8%148.43+165.9%55.82+72.9%32.29+384.8%6.66

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/20242024Q39/30/2024
Total Revenue2.51+15.7%0.79+61.2%1.08-12.9%1.16-60.9%2.170.49-49.5%1.24-19.0%2.97+141.5%
Cost of Goods Sold Incl. D&A0.59+59.5%0.46+21.1%0.42+10.5%0.37+23.3%0.37+15.6%0.38+18.8%0.38+31.0%0.30+36.4%
Gross Profit1.92+6.7%0.33+200.0%0.67-21.2%0.79-70.4%1.800.11-83.1%0.85-31.5%2.67+167.0%
Selling, General and Administrative Excl. Other12.23+41.4%9.12+9.9%9.08-20.3%8.56-31.1%8.65-25.4%8.30-23.7%11.39+5.4%12.43+9.6%
Research and Development7.59+18.8%6.11+12.5%6.07-28.2%5.82-38.6%6.39-24.6%5.43-32.3%8.45+6.6%9.48+18.8%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.31-8.79-8.41-7.78-6.84-8.19-10.54-9.76
Interest Expense6.63+74.0%5.56+54.4%4.83+47.3%4.35+49.0%3.81+40.1%3.60+97.8%3.28+126.2%2.92+147.5%
Unusual Expense-91.02-1683.0%101.06111.1814.645.75-5.20-139.9%-16.29-283.2%-6.90-135.0%
Net Income Before Taxes74.14-115.35-124.30-4880.8%-26.68-16.30-281.3%-6.532.60-5.48
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income74.14-115.35-124.30-4880.8%-26.68-16.30-281.3%-6.532.60-5.48
Net Income From Continuing Operations74.14-115.35-124.30-4880.8%-26.68-16.30-281.3%-6.532.60-5.48
Net Income74.14-115.35-124.30-4880.8%-26.68-16.30-281.3%-6.532.60-5.48
EPS (Recurring) per share-1.30-1.22-1.28-0.45-0.34-0.28-0.15-0.29
EPS (Basic, Before Extraordinaries) per share2.02-3.16-3.42-4985.7%-0.74-0.45-280.0%-0.180.07-0.15
EPS (Diluted) per share-0.27-3.16-3.42-8650.0%-0.74-0.45-0.180.04-0.15
EBITDA-9.72-8.33-7.99-7.41-6.48-7.81-10.16-9.46
Non-Operating Income (Expense)0.07-36.4%0.060.0%0.130.0%0.09-69.0%0.11-50.0%0.06+20.0%0.13+85.7%0.29+480.0%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.39+494.7%1.07+37.2%0.63+80.0%0.62-7.5%0.57-57.1%0.78+47.2%0.35+84.2%0.67
Price To Sales Ratio ratio72.5371.9146.5421.3610.0111.2421.1315.68
Gross Margin %76.4542.0861.4768.0883.1323.2269.2389.91
Operating Margin %-410.84-1,113.43-775.21-670.92-315.54-1,668.23-853.36-328.15
Net Margin %2,953.82-14,619.26-11,456.04-2,301.55-751.27-1,330.14210.53-184.36
Shares Outstanding million shares37.15+2.7%36.43+0.7%36.43+0.7%36.23+0.1%36.19+0.1%36.19+0.2%36.18+0.2%36.18+0.2%
Market Capitalization138.32+101.1%375.12+610.1%228.64+241.6%107.96+25.9%68.77-30.8%52.83-65.0%66.94-42.8%85.75-20.9%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments8.69-6.5%9.29-31.3%13.52-9.0%14.85+44.3%10.29+6.6%9.65+60.0%6.03-37.6%9.66+88.3%5.13
Short Term Receivables0.47-36.5%0.74-78.0%3.36+73.2%1.94-35.1%2.99+433.9%0.560.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.51+18.9%1.27-44.1%2.27-77.9%10.26+496.5%1.72+168.8%0.64+3.2%0.62-11.4%0.70+180.0%0.25
Total Current Assets10.67-5.7%11.31-40.9%19.15-29.2%27.05+80.5%14.99+38.2%10.85+62.9%6.66-35.7%10.36+92.6%5.38
Net Property, Plant & Equipment46.10-16.1%54.93-4.1%57.28+22.8%46.65+22.5%38.07+196.5%12.84+205.0%4.21+29.5%3.25+296.3%0.82
Total Investments and Advances5.39-1.6%5.48-4.2%5.72-4.0%5.96+396.7%1.200.0%1.20+71.4%0.70-12.5%0.800.00
Intangible Assets13.750.0%13.750.0%13.750.0%13.750.0%13.750.0%13.750.0%13.750.00-100.0%4.94
Deferred Tax Assets9.31-27.8%12.89+11.1%11.60-3.7%12.04+20.0%10.03+232.1%3.02---
Other Assets0.970.0%0.97-60.7%2.47+1.6%2.43+38.9%1.75+96.6%0.89+535.7%0.140.0%0.140.00
Total Assets86.19-13.2%99.33-9.7%109.96+1.9%107.88+35.2%79.80+87.6%42.53+67.1%25.45+75.0%14.54+30.5%11.14
Short Term Debt Incl. Current Port. of LT Debt4.56-89.5%43.38+357.6%9.48-44.3%17.01+1026.5%1.51-33.5%2.27+73.3%1.310.000.00
Accounts Payable0.92+19.5%0.77-51.3%1.58-73.8%6.03+165.6%2.27+136.5%0.96+74.5%0.55+34.1%0.41-29.3%0.58
Other Current Liabilities3.46-15.6%4.10-23.9%5.39+194.5%1.83+77.7%1.03-70.4%3.48+15.2%3.02+86.4%1.62+16.5%1.39
Total Current Liabilities8.95-81.5%48.25+193.1%16.46-33.8%24.87+417.0%4.81-28.3%6.71+37.5%4.88+140.4%2.03+3.0%1.97
Long Term Debt283.45+241.0%83.13-25.0%110.89+248.7%31.80-12.8%36.48+235.3%10.88+601.9%1.550.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities12.38-22.5%15.97+8.8%14.68-2.9%15.12+15.3%13.11+114.9%6.10+98.1%3.080.00-100.0%1.15
Other Liabilities0.000.000.000.000.000.00-100.0%1.35-72.0%4.82+1562.1%0.29
Total Liabilities304.79+106.8%147.35+3.7%142.03+97.8%71.80+32.0%54.40+129.7%23.68+118.0%10.86+58.5%6.85+100.9%3.41
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-218.60-48.02-32.06-188.9%36.08+42.0%25.40+34.7%18.86+29.3%14.59+89.7%7.69-0.5%7.73
Total Shareholders Equity-218.60-48.02-32.06-188.9%36.08+42.0%25.40+34.7%18.86+29.3%14.59+89.7%7.69-0.5%7.73
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-218.60-48.02-32.06-188.9%36.08+42.0%25.40+34.7%18.86+29.3%14.59+89.7%7.69-0.5%7.73
Total Liabilities & Stockholders Equity86.19-13.2%99.33-9.7%109.96+1.9%107.88+35.2%79.80+87.6%42.53+67.1%25.45+75.0%14.54+30.5%11.14
Book Value Per Share per share-6.00-1.33-0.89-189.0%1.00+6.4%0.94-6.9%1.01-31.3%1.47-93.1%21.25+86.6%11.39
Tangible Book Value Per Share per share-6.38-1.71-1.27-304.8%0.62+44.2%0.43+59.3%0.27+200.0%0.09-99.6%21.25+415.8%4.12
Full-Time Employees people61+1.7%60-9.1%66-12.0%75+8.7%69+16.9%59+55.3%38+22.6%31-8.8%34
Price to Book Ratio ratio-0.60-1.31-9.450.985.852.962.210.790.97
Return on Assets %-187.36-18.08-63.39-39.34-37.85-65.25-104.34-130.06-87.53
Return on Equity %---3,439.35-120.10-104.65-132.62-168.89-216.56-147.11
Return on Invested Capital %-267.97-53.87-87.59-54.38-37.42-74.60-120.63-217.08-166.06
Quick Ratio ratio1.190.231.161.093.111.621.365.102.74
Current Ratio ratio1.190.231.161.093.111.621.365.102.74

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income-192.18-173.80-18.92-69.05-36.92-23.16-22.18-19.48-16.70
Depreciation1.841.53+15.9%1.32+36.1%0.97+9.0%0.89-23.9%1.17+5.4%1.11-17.8%1.350.0%1.35
Other Funds (Non Cash)165.15147.92-17.86-158.9%30.30+877.4%3.10+90.2%1.63-55.6%3.67-22.6%4.74-8.8%5.20
Funds from Operations-25.19-24.35-35.45-37.78-32.92-20.35-17.40-13.70-10.43
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.23-1.41-2.10-9.65-2293.2%0.44-3.22-0.87-1.88-0.19
Cash from Operating Activities-25.42-25.76-37.55-47.42-32.48-23.57-18.27-15.58-10.63
Capital Expenditures-0.37-0.54-1.88-8.14-2.21-1.30-0.82-0.22-0.88
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00-100.0%0.010.000.000.00-100.0%0.09+28.6%0.07
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00-100.0%9.62
Purchase of Investments0.000.000.000.000.000.000.000.00-3.39
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00-100.0%13.02
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00-100.0%3.010.00
Cash from Investing Activities-0.37-0.54-1.88-8.13-2.21-1.30-0.82-128.5%2.88-67.3%8.81
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.240.66+407.7%0.13+1200.0%0.01-100.0%44.52+65.3%26.93+16.8%23.06+131.3%9.970.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.240.66+407.7%0.13+1200.0%0.01-100.0%44.52+65.3%26.93+16.8%23.06+131.3%9.970.00
Proceedsfrom Stock Options2.370.000.000.00-100.0%44.39+68.7%26.32+15.0%22.89+129.6%9.970.00
Issuance or Reduction of Debt, Net40.0025.00-28.3%34.89-35.4%54.030.000.00-100.0%0.720.000.00
Change in Long Term Debt40.0025.00-28.3%34.89-35.4%54.030.000.000.000.000.00
Issuance of Long Term Debt40.0025.00-28.3%34.89-35.4%54.030.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.10-0.05-0.06-0.04-0.50-1.41-0.57-1.000.00
Other Financing Activities Uses-0.10-0.05-0.06-0.04-0.50-1.41-0.57-1.000.00
Cash from Financing Activities44.1525.61-26.7%34.96-35.2%53.99+22.6%44.02+72.5%25.52+10.0%23.21+158.8%8.970.00
Net Change in Cash18.35-0.69-4.47-1.57-116.8%9.32+1356.3%0.64-84.5%4.12-3.73-1.81
Free Cash Flow-25.79-26.30-39.43-55.57-34.69-24.88-19.09-15.81-11.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-0.31-0.29

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/20242024Q39/30/2024
Cash & Short Term Investments23.95+453.1%4.75-59.4%8.69-6.5%14.76-13.9%4.33-83.6%11.69-69.1%9.29-31.3%17.14-28.5%
Short Term Receivables2.53+16.6%0.05-79.2%0.47-36.5%0.76-65.8%2.17+75.0%0.24-86.0%0.74-78.0%2.22-73.9%
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.67-34.3%1.15-7.3%1.51+18.9%1.42-53.1%1.02-68.7%1.24-42.1%1.27-44.1%3.03-26.6%
Total Current Assets27.16+261.2%5.95-54.8%10.67-5.7%16.93-24.4%7.52-75.7%13.17-68.4%11.31-40.9%22.39-38.8%
Net Property, Plant & Equipment44.11-17.0%45.17-16.3%46.10-16.1%52.48-6.1%53.16-7.0%53.97-5.2%54.93-4.1%55.87+3.2%
Total Investments and Advances4.12-23.6%4.12-23.6%5.39-1.6%5.39-1.6%5.39-1.6%5.39-1.6%5.48-4.2%5.48-5.8%
Intangible Assets13.750.0%13.750.0%13.750.0%13.750.0%13.750.0%13.750.0%13.750.0%13.750.0%
Deferred Tax Assets--9.31-27.8%---12.89+11.1%-
Other Assets0.81-16.5%0.81-16.5%0.970.0%0.97+27.6%0.97-6.7%0.97-60.7%0.97-60.7%0.76-69.2%
Total Assets89.95+11.3%69.80-20.0%86.19-13.2%89.52-8.9%80.79-25.4%87.25-27.5%99.33-9.7%98.24-12.9%
Short Term Debt Incl. Current Port. of LT Debt246.11+110.7%4.59-95.7%4.56-89.5%135.60+20.6%116.82-1.0%107.24+2.9%43.38+357.6%112.40+736.3%
Accounts Payable1.19+24.0%0.66-32.7%0.92+19.5%1.28-29.3%0.96-44.8%0.98-52.4%0.77-51.3%1.81-52.0%
Other Current Liabilities2.90+26.1%3.98+71.6%3.46-15.6%3.06-23.3%2.30-33.3%2.32-39.3%4.10-23.9%3.99-14.6%
Total Current Liabilities250.20+108.4%9.23-91.7%8.95-81.5%139.95+18.4%120.08-2.5%110.54+0.4%48.25+193.1%118.20+440.2%
Long Term Debt67.85+150.1%369.08+1246.0%283.45+241.0%42.08+50.7%27.13-3.7%27.42-57.0%83.13-25.0%27.93-72.1%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities3.080.0%3.080.0%12.38-22.5%3.080.0%3.080.0%3.080.0%15.97+8.8%3.080.0%
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities321.12+113.7%381.39+170.4%304.79+106.8%185.10+24.1%150.29-2.7%141.03-20.3%147.35+3.7%149.21+19.2%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity-231.17-311.59-218.60-95.59-69.50-53.78-48.02-50.97
Total Shareholders Equity-231.17-311.59-218.60-95.59-69.50-53.78-48.02-50.97
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity-231.17-311.59-218.60-95.59-69.50-53.78-48.02-50.97
Total Liabilities & Stockholders Equity89.95+11.3%69.80-20.0%86.19-13.2%89.52-8.9%80.79-25.4%87.25-27.5%99.33-9.7%98.24-12.9%
Book Value Per Share per share-6.22-8.55-6.00-2.64-1.92-1.49-1.33-1.41
Tangible Book Value Per Share per share-6.59-8.93-6.38-3.02-2.30-1.87-1.71-1.79
Full-Time Employees people--61+1.7%---60-9.1%-
Price to Book Ratio ratio-0.60-1.20-2.38-1.55-1.28-1.10-1.31-1.86
Return on Assets %-225.11-359.90-187.36-49.96-27.19-0.41-18.08-39.21
Return on Invested Capital %--200.62-191.65---7.41-
Quick Ratio ratio0.110.641.190.120.060.120.230.19
Current Ratio ratio0.110.641.190.120.060.120.230.19

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/20242024Q39/30/2024
Net Income74.14-115.35-124.30-4880.8%-26.68-16.30-281.3%-6.532.60-5.48
Depreciation0.59+59.5%0.46+21.1%0.42+10.5%0.37+19.4%0.37+15.6%0.38+18.8%0.38+31.0%0.31+40.9%
Other Funds (Non Cash)-80.49-851.5%108.21117.2420.1910.71-0.23-101.5%-12.10-211.1%-2.76-113.0%
Funds from Operations-5.76-6.68-6.64-6.11-5.21-6.38-9.12-7.93
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.910.90-0.03-102.5%1.81-2.00-1.201.19+112.5%-0.94-1144.4%
Cash from Operating Activities-8.67-5.78-6.67-4.30-7.21-7.58-7.93-8.86
Capital Expenditures-0.02-0.06-0.05-162.5%-0.24-0.15-0.100.08-0.34
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00-100.0%0.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.06-0.05-162.5%-0.24-0.15-0.100.08-0.34
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock2.880.700.660.000.00-100.0%0.00-100.0%0.000.00-100.0%
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.880.700.660.000.00-100.0%0.00-100.0%0.000.00-100.0%
Proceedsfrom Stock Options2.370.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net25.000.00-100.0%0.0015.000.0010.00-71.3%0.000.00-100.0%
Change in Long Term Debt25.000.00-100.0%0.0015.000.0010.00-71.3%0.000.00-100.0%
Issuance of Long Term Debt25.000.00-100.0%0.0015.000.0010.00-71.3%0.000.00-100.0%
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.060.00-0.030.00-0.010.00-0.06
Other Financing Activities Uses0.00-0.060.00-0.030.00-0.010.00-0.06
Cash from Financing Activities27.880.64-93.6%0.6614.970.00-100.0%9.99-71.4%0.00-0.06-100.2%
Net Change in Cash19.20-5.20-325.1%-6.0710.43-7.362.31-90.4%-7.85-9.26-179.8%
Free Cash Flow-8.68-5.84-6.73-4.54-7.36-7.68-7.85-9.20

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.67%0.9M11.9M188.21K
2026-10-157.56%0.9M11.9M203.68K
2026-09-308.33%1.0M11.6M212.94K
2026-09-158.32%1.0M11.6M236.31K
2026-08-317.65%0.9M11.6M150.79K
2026-08-147.21%0.8M11.6M148.69K
2026-07-317.49%0.9M11.4M140.28K
2026-07-156.16%0.7M11.4M123.40K
2026-06-303.82%0.4M11.6M105.96K
2026-06-151.79%0.2M11.6M62.43K
2026-05-291.82%0.2M11.5M59.34K
2026-05-151.99%0.2M11.3M56.81K
2026-04-302.04%0.2M11.3M51.27K
2026-04-152.17%0.2M11.3M44.54K
2026-03-312.68%0.3M11.1M47.87K
2026-03-132.82%0.3M11.0M47.28K
2026-02-272.70%0.3M11.0M51.40K
2026-02-132.70%0.3M11.0M53.87K
2026-01-302.49%0.3M11.0M66.35K
2026-01-152.01%0.2M11.0M294.65K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.054.000.0021.1720.000.000.818-0.0570.001
call5.000.000.300.036.1356.000.000.538-0.0810.002
call7.500.004.200.904.72510.000.000.259-0.0540.002
call10.000.000.750.405.2804.000.000.230-0.0550.002
call12.500.000.153.206.4551.000.000.217-0.0660.002
call15.000.004.200.805.9662.000.000.127-0.0440.001
call17.500.004.200.006.4000.000.000.122-0.0460.001
call20.000.004.200.006.7650.000.000.118-0.0470.001
put2.500.000.550.105.9021.000.00-0.173-0.0520.002
put5.001.101.502.002.88650.000.00-0.662-0.0380.002
put7.501.956.000.0014.4640.000.00-0.741-0.0530.002
put10.004.408.500.0018.8220.000.00-0.768-0.0610.002
put12.506.9011.000.0019.5340.000.00-0.866-0.0400.001
put15.009.4013.500.0020.0960.000.00-0.873-0.0420.001
put17.5011.9016.000.0020.5590.000.00-0.878-0.0440.001
put20.0014.4018.500.0020.9530.000.00-0.882-0.0450.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-128-KCurrent report2026-11-12SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-208-KCurrent report2026-07-20SEC
2026-07-208-KCurrent report2026-07-17SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-07-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-248-K/A2026-04-24SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-168-KCurrent report2026-06-11SEC
2026-05-13SCHEDULE 13D/ASEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-12SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-284Statement of changes in beneficial ownership of securities2026-04-24SEC
2026-04-283Initial statement of beneficial ownership of securities2026-04-24SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-278-KCurrent report2026-04-24SEC
2026-04-028-KCurrent report2026-04-02SEC
2026-03-2510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-258-KCurrent report2026-03-25SEC
2026-03-198-KCurrent report2026-03-19SEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-14SEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-14SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Madison Asset Management, LLC5.67%
BlackRock, Inc.1.53%
VANGUARD CAPITAL MANAGEMENT LLC1.33%
MILLENNIUM MANAGEMENT LLC1.28%
GEODE CAPITAL MANAGEMENT, LLC0.75%
Dauntless Investment Group, LLC0.56%
STATE STREET CORP0.50%
Grey Ledge Advisors, LLC0.27%
NORTHERN TRUST CORP0.24%
VANGUARD PORTFOLIO MANAGEMENT LLC0.22%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.95%
iShares Russell 2000 ETF0.54%
Fidelity Small Cap Index Fund0.35%
VANGUARD EXTENDED MARKET INDEX FUND0.34%
iShares Russell 2000 Growth ETF0.30%
VANGUARD RUSSELL 2000 INDEX FUND0.18%
Fidelity Extended Market Index Fund0.15%
Ultra-Small Company Market Fund0.11%
iShares Micro-Cap ETF0.11%
Schwab Small-Cap Index Fund0.08%

OakChart. ARMP. Cached 15 minutes. Terms

Some panels did not load: insider.